孟鲁司特钠对婴幼儿哮喘的早期干预作用

Clinical study on early intervention of infant asthma with montelukast

目的观察孟鲁司特钠对婴幼儿哮喘的早期干预作用。方法将120例婴幼儿哮喘者随机分为对照组和干预组,对照组予以常规抗炎、止喘以及支持对症治疗;治疗组在常规治疗基础上加用孟鲁司特钠,疗程为1年。比较各组患儿临床症状改善情况以及干预结束后对血嗜酸性粒细胞阳离子蛋白(ECP)、血嗜酸性粒细胞(Eos)以及血总IgE(tIgE)水平的影响。结果孟鲁司特钠干预组急性期临床症状改善情况明显好予对照组(P<0.05),且经过一年的干预后治疗后孟鲁司特钠干预组血总ECP水平、Eos水平以及tIgE水平均明显低于对照组,结果有显著差异(P<0.05),1年内孟鲁司特钠干预组喘息以及下呼吸道感染的次数明显少于对照组(P<0.01)。结论孟鲁司特钠长期使用可以减少婴幼儿哮喘患儿喘息的发作次数,可以减少其反复发生下呼吸道感染的概率,同时在急性期常规治疗的基础上加用孟鲁司特钠可以缩短病程改善症状。

Objective To evaluate the therapeutic effects of early intervention with montelukast for infant asthma. Methods 60 patients with asthma were received therapy in combination with traditional treatment and montelukast, and compared with those of 60 cases of asthma with traditional treatment. The changes on the clinical symptom, eosinophile cationic protein, eosinophile granulocyte and immunoglobulin E were compared between two groups. Results Early intervention of asthma with montelukast could improve the clinical symptom（ P 〈 0.05 vs control group） , reduce the level of eosinophile cationic protein, eosinophile granulocyte and immunoglobulin E （P 〈 0. 05 vs control group）, and decrease the ncidence rate of lower respiratory infection and gasp （P 〈0. 01 vs control group）. Conclusion It is suggested that the approach on early intervention with montelukast has a good effect for the infant asthma.